Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs

  • ID: 3250618
  • Report
  • Region: Asia Pacific
  • 126 Pages
  • GBI Research
1 of 4
The value of the RA market in the APAC region amounted to an estimated $5.6 billion in 2014

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen
  • Biogen IDEC
  • Galapagos
  • Johnson & Johnson
  • Roche
  • MORE
This report provides in-depth analysis of Rheumatoid Arthritis (RA) market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2014, along with market forecast until 2021. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the RA market in the APAC region amounted to an estimated $5.6 billion in 2014 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.3% to reach $6.9 billion by 2021. The key drivers for growth in the APAC market include: the increasing prevalent population and the anticipated market launch of promising pipeline candidates. The late-stage pipeline which has a potential to stimulate growth during the forecast period include interleukin (IL)-6 inhibitors Sanofi/Regeneron’s sarilumab, Johnson & Johnson/GlaxoSmithKline’s [J&J/GSK’s] sirukumab, small molecules (four janus kinase [JAK] inhibitors: Eli Lilly/Incyte’s baricitinib, Loss of patent exclusitivity of major second-line biologic anti-TNF during such as Enbrel, Remicade and Humira by the end of the forecast period is the major barrier for growth in the RA market size in the APAC markets. Preference for less expensive alternatives to branded medicines, such as biosimilars and other alternate therapies is another major barrier in cost-conscious APAC markets, India and China.

Scope:

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for RA. It covers and includes:
- A brief introduction to RA, including the disease’s pathophysiology, risk factors, diagnosis and an overview of pharmacotherapy and treatment algorithms.
- In-depth analysis of the drug combinations used in the treatment of RA, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy
- A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration
- Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action
- Multi-scenario forecast market data to 2021, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets
- Discussion of the drivers and barriers for market growth
- In-depth analysis of licensing and co-development deals involving drugs indicated in RA, including an outline of the key deals

Reasons to Purchase:

Primarily, the report will allow clients to gain a strong understanding of RA, helping to identify and clarify market opportunities and the competitive environment. It will also allow you to:
- Understand the RA pipeline and the key trends in the current product development landscape
- Observe detailed profiles for the promising pipeline products, including revenue forecasts, and gain an insight into how they are likely to compete in the market, and what their main competitors will be
- Follow the trends in RA clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs for RA therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates
- Observe the potential growth patterns expected for the RA market over the forecast period, and identify which countries are expected to make the biggest contribution to this growth.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen
  • Biogen IDEC
  • Galapagos
  • Johnson & Johnson
  • Roche
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.5.1 Physical Examination
2.5.2 Blood Tests
2.5.3 1987 Rheumatoid Arthritis Classification
2.5.4 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis
2.6 Epidemiology
2.7 Co-morbidities and Complications
2.8 Disease Progression
2.9 Pharmacotherapy Algorithm
2.10 Treatment Options
2.10.1 Pharmacological
2.10.2 Methotrexate
2.10.3 Hydroxychloroquine
2.10.4 Leflunomide
2.10.5 Sulfasalazine
2.10.6 Cyclosporine
2.10.7 Prograf (tacrolimus)
2.10.8 Xeljanz (tofacitinib)
2.11 Other Non-biologics
2.11.1 Non-steroidal Anti-inflammatory Drugs
2.11.2 Painkillers
2.11.3 Glucocorticoids
2.12 Biologic Disease-Modifying Anti-rheumatic Drugs
2.12.1 Tumor Necrosis Factor Alpha Inhibitors
2.12.2 Interleukin Inhibitors
2.12.3 Other Biologics that Target B- and T-Cell Antigens
2.13 Disease Scoring Methods for Measuring Treatment Efficacy
2.13.1 Radiographic Progression
2.13.2 Clinical Disease Activity Index and Simplified Disease Activity Index
2.13.3 Disease Activity Score-28
2.13.4 American College of Rheumatology
2.13.5 Health Assessment Questionnaire

3 Marketed Products
3.1 Overview
3.2 Small-Molecule Disease-Modifying Anti-rheumatic Drugs
3.2.1 Methotrexate-Based Products
3.2.2 Xeljanz (tofacitinib) - Pfizer
3.3 Biologic Disease-Modifying Anti-rheumatic Drugs
3.3.1 Remicade (infliximab) - Johnson & Johnson, Merck
3.3.2 Humira (adalimumab) - AbbVie
3.3.3 Enbrel (etanercept) - Amgen, Pfizer and Takeda Pharmaceutical
3.3.4 Rituxan (rituximab) - Genentech, Biogen IDEC
3.3.5 Orencia (abatacept) - Bristol-Myers Squibb
3.3.6 Simponi (golimumab) - Johnson & Johnson, Merck
3.3.7 Cimzia (certolizumab pegol) - UCB
3.3.8 Kineret (anakinra) - Swedish Orphan Biovitrum
3.3.9 Actemra (tocilizumab) - Roche
3.3.10 Comparative Safety and Efficacy
3.4 Unmet Need

4 Product Pipeline
4.1 Overview
4.2 Pipeline Distribution by Phase of Development, Molecule Type, Route of Administration and Novelty
4.3 Pipeline Distribution by Mechanism of Action
4.3.1 Cytokine Inhibitors
4.3.2 B- and T-cells
4.3.3 Intracellular Kinases
4.4 Clinical Trial Analysis
4.4.1 Overall Attrition Rate
4.4.2 Attrition Rate by Phase, Molecule Type and Target
4.4.3 Average Clinical Trial Size by Molecule Type
4.4.4 Average Clinical Trial Size by Mechanism of Action
4.4.5 Average Clinical Trial Duration per Molecule Type by Product
4.4.6 Average Clinical Trial Duration per Mechanism of Action by Product
4.4.7 Primary and Secondary Endpoints
4.4.8 Summary
4.5 Promising Pipeline Drugs
4.5.1 Baricitinib - Eli Lilly
4.5.2 Sarilumab - Regeneron Pharmaceuticals/Sanofi
4.5.3 Sirukumab - Johnson & Johnson
4.5.4 Decernotinib - Vertex Pharmaceuticals
4.5.5 Masitinib
4.5.6 Denosumab
4.6 Comparative Heat Map

5 Market Forecasts
5.1 Asia-Pacific
5.1.1 Treatment Usage Patterns
5.1.2 Market Size
5.2 India
5.2.1 Treatment Usage Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 China
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Australia
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Usage Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers of Rheumatoid Arthritis Therapeutics Market
5.6.1 Drivers
5.6.2 Barriers

6 Deals
6.1 Licensing Agreements
6.1.1 Deal Values by Therapeutic Molecule Type
6.1.2 Deal Values by Therapeutic Mechanism of Action
6.1.3 AstraZeneca Enters into Licensing Agreement with Rigel Pharma for Fostamatinib Disodium
6.1.4 Alder Biopharmaceuticals Enters into Licensing Deal with Bristol-Myers Squibb and Alder Biopharmaceuticals for Clazakizumab
6.1.5 Janssen Biotech Enters into a Licensing Deal with Astellas Pharma for Peficitinib
6.1.6 Ablynx Enters into a Licensing Deal with AbbVie for the Nanobody ALX-006
6.2 Co-development
6.2.1 Deal Values by Therapeutic Molecule Type and Phase
6.2.2 Deal Values by Therapeutic Mechanism of Action and Phase
6.2.3 GlaxoSmithKline enters into Global Agreement with Archemix
6.2.4 Abbott Laboratories Enters into Global Collaboration with Galapagos for filgotinib
6.2.5 Chroma Therapeutics Enters into a Co-development Agreement with GlaxoSmithKline

7 Appendix
7.1 All Pipeline Drugs by Phase of Development
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND-CTA Filed
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.2 Market Forecasts to 2021
7.3 Abbreviations
7.4 Bibliography
7.4.1 References for Figure 10
7.4.2 References for Figure 26
7.5 Research Methodology
7.5.1 Coverage
7.5.2 Secondary Research
7.5.3 Primary Research
7.5.4 Therapeutic Landscape
7.5.5 Geographical Landscape
7.5.6 Pipeline Analysis
7.6 Expert Panel Validation
7.7 Contact Us
7.8 Disclaimer

1.1 List of Tables:
Table 1: ACR-EULAR Classification Criteria for Rheumatoid Arthritis, 2010
Table 2: Rheumatoid Arthritis, Therapeutics, Global, All Pipeline Products, Discovery, 2014
Table 3: Rheumatoid Arthritis, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014
Table 4: Rheumatoid Arthritis, Therapeutics, Global, All Pipeline Products, IND/CTA-Filed, 2014
Table 5: Rheumatoid Arthritis, Therapeutics, Global, All Pipeline Products, Phase I, 2014
Table 6: Rheumatoid Arthritis, Therapeutics, Global, All Pipeline Products, Phase II, 2014
Table 7: Rheumatoid Arthritis, Therapeutics, Global, All Pipeline Products, Phase III, 2014
Table 8: Rheumatoid Arthritis, Therapeutics Market, Asia-Pacific, Market Forecast, 2014-2021
Table 9: Rheumatoid Arthritis, Therapeutics Market, India, Market Forecast, 2014-2021
Table 10: Rheumatoid Arthritis, Therapeutics Market, China, Market Forecast, 2014-2021
Table 11: Rheumatoid Arthritis, Therapeutics Market, Australia, Market Forecast, 2014-2021
Table 12: Rheumatoid Arthritis, Therapeutics Market, Japan, Market Forecast, 2014-2021
Table 13: Abbreviations

1.2 List of Figures:
Figure 1: American College of Rheumatology Treatment Guidelines, 2012
Figure 2: Rheumatoid Arthritis Market, Global, Annual Sales of Remicade ($bn), 2008-2014
Figure 3: Rheumatoid Arthritis Market, Global, Annual Sales of Humira ($bn), 2008-2014
Figure 4: Rheumatoid Arthritis Market, Global, Annual Sales of Enbrel ($bn), 2008-2014
Figure 5: Rheumatoid Arthritis Market, Global, Annual Sales of Rituxan ($bn), 2008-2014
Figure 6: Rheumatoid Arthritis Market, Global, Annual Sales of Orencia ($m), 2008-2014
Figure 7: Rheumatoid Arthritis Market, Global, Annual Sales of Simponi ($m), 2009-2014
Figure 8: Rheumatoid Arthritis Market, Global, Annual Sales of Cimzia ($m), 2008-2014
Figure 9: Rheumatoid Arthritis Market, Global, Annual Sales of Actemra ($m), 2008-2014
Figure 10: Comparative Efficacy and Safety of Marketed Products
Figure 11: Rheumatoid Arthritis Market, Global, Pipeline, 2014
Figure 12: Rheumatoid Arthritis Market, Global, Pipeline by Mechanism of Action, 2014
Figure 13: Rheumatoid Arthritis Market, Global, Pipeline, Cytokine Inhibitors, 2014
Figure 14: Rheumatoid Arthritis Market, Global, Pipeline, Inhibitors of B and T Cells, 2014
Figure 15: Rheumatoid Arthritis Market, Global, Pipeline, Intracellular Kinase Inhibitors, 2014
Figure 16: Rheumatoid Arthritis, Global, Clinical Trial Failure Rate (%), 2006-2014
Figure 17: Rheumatoid Arthritis, Global, Clinical Trial Failure Rate (%), 2006-2014
Figure 18: Rheumatoid Arthritis, Global, Clinical Trial Failure Rate (%), 2006-2014
Figure 19: Rheumatoid Arthritis Market, Global, Pipeline, Clinical Trial Size by Molecule Type by Product, 2006-2014
Figure 20: Rheumatoid Arthritis Market, Global, Pipeline, Clinical Trial Size by Molecule Type by Trial, 2006-2014
Figure 21: Rheumatoid Arthritis Market, Global, Pipeline, Clinical Trial Size by Mechanism of Action by Product, 2006-2014
Figure 22: Rheumatoid Arthritis Market, Global, Pipeline, Clinical Trial Size by Mechanism of Action by Trial, 2006-2014
Figure 23: Rheumatoid Arthritis Market, Global, Pipeline, Clinical Trial Duration by Molecule Type by Product (months), 2006-2014
Figure 24: Rheumatoid Arthritis Market, Global, Pipeline, Clinical Trial Duration by Mechanism of Action by Product (months), 2006-2014
Figure 25: Rheumatoid Arthritis Market, Global, Frequency of Primary Endpoints Measured in Clinical Trials, 2006-2014
Figure 26: Comparative Efficacy and Safety of Pipeline Programs
Figure 27: Rheumatoid Market, Asia-Pacific, Treatment Usage Patterns (million), 2014-2021
Figure 28: Rheumatoid Market, Asia-Pacific, Market Size ($bn), 2014-2021
Figure 29: Rheumatoid Market, India, Treatment Usage Patterns (million), 2014-2021
Figure 30: Rheumatoid Market, India, Annual Cost of Therapy ($), 2014-2021
Figure 31: Rheumatoid Market, India, Market Size ($m), 2014-2021
Figure 32: Rheumatoid Market, China, Treatment Usage Patterns (million), 2014-2021
Figure 33: Rheumatoid Market, China, Annual Cost of Therapy ($), 2014-2021
Figure 34: Rheumatoid Market, China, Market Size ($m), 2014-2021
Figure 35: Rheumatoid Market, Australia, Treatment Usage Patterns (‘000), 2014-2021
Figure 36: Rheumatoid Market, Australia, Annual Cost of Therapy ($), 2014-2021
Figure 37: Rheumatoid Market, Australia, Market Size ($m), 2014-2021
Figure 38: Rheumatoid Market, Japan, Treatment Usage Patterns (‘000), 2014-2021
Figure 39: Rheumatoid Market, Japan, Annual Cost of Therapy ($), 2014-2021
Figure 40: Rheumatoid Market, Japan, Market Size ($bn), 2014-2021
Figure 41: Rheumatoid Arthritis Market, Global, Licensing Deals, 2006-2014
Figure 42: Rheumatoid Arthritis Market, Global, Licensing Deals, 2006-2014
Figure 43: Rheumatoid Arthritis Market, Global, Licensing Deals, 2006-2014
Figure 44: Rheumatoid Arthritis Market, Global, Co-development Deals, 2006-2014
Figure 45: Rheumatoid Arthritis Market, Global, Co-development Deals, 2006-2014
Figure 46: Rheumatoid Arthritis Market, Global, Co-development Deals, 2006-2014
Figure 47: Research Market Forecasting Model
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- AbbVie
- Abbott Laboratories
- Ablynx
- Alder Biopharmaceuticals
- Amgen
- Archemix
- Astellas Pharma
- AstraZeneca
- Biogen IDEC
- Bristol-Myers Squibb
- Chroma Therapeutics
- Eli Lilly
- Galapagos
- Genentech
- GlaxoSmithKline
- Janssen Biotech
- Johnson & Johnson
- Merck
- Pfizer
- Regeneron Pharmaceuticals/Sanofi
- Rigel Pharma
- Roche
- Takeda Pharmaceutical
- UCB
- Vertex Pharmaceuticals

Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll